Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications

International Journal of Impotence Research volume 19, pages 386–392 (2007)Cite this article

Abstract

In a large-scale epidemiology study, 50% of aging men reported erectile dysfunction (ED) or ejaculatory dysfunction (EjD), with lower urinary tract symptoms (LUTS) an independent risk factor for each of these conditions. In light of the shift from urologists (UROs) to primary care/internal medicine physicians (PCPs) for the initial management of men with LUTS associated with benign prostatic hyperplasia (BPH), a survey was conducted to assess the perceptions of UROs and PCPs regarding sexual dysfunction (SD) in men with LUTS/BPH and the effects of BPH treatments (α1-adrenergic receptor antagonists (α-blockers) and 5α-reductase inhibitors (5ARIs)) on sexual function. The survey was mailed to 7500 UROs and 2500 PCPs, with 1275 (13%) surveys returned (1087 by UROs, 177 by PCPs and 11 by other specialty). α-Blocker monotherapy was the most common medication prescribed by both UROs (56%) and PCPs (47%). UROs estimated that 19% of their patients with LUTS/BPH experienced SD owing to their symptoms compared with the estimate of 27% by PCPs. UROs estimated that 19% of their patients experienced SD owing to their BPH medication compared with the PCP estimate of 24%. The incidence of EjD owing to BPH medications estimated by UROs (32%) was higher than that estimated by PCPs (22%); the rate of ED estimated by PCPs (34%) was higher than that estimated by UROs (23%). UROs were more aware than PCPs of the specific sexual side effects caused by α-blockers versus 5ARIs. These results suggest that physicians are underestimating the prevalence of SD in men with LUTS/BPH. As men with LUTS/BPH are at increased risk for SD, physicians should be especially cognizant of BPH treatment-related sexual side effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL . The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–479.

    Article  CAS  Google Scholar 

  2. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL . Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997; 31: 272–280.

    Article  CAS  Google Scholar 

  3. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428–436.

    Article  CAS  Google Scholar 

  4. Welch G, Weinger K, Barry MJ . Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002; 59: 245–250.

    Article  Google Scholar 

  5. Blanker MH, Bosch JL, Groeneveld FP et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57: 763–768.

    Article  CAS  Google Scholar 

  6. Blanker MH, Bohnen AM, Groeneveld FP et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49: 436–442.

    Article  CAS  Google Scholar 

  7. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.

    Article  Google Scholar 

  8. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677–685.

    Article  CAS  Google Scholar 

  9. Tubaro A, Polito M, Giambroni L, Famulari C, Gange E, Ostardo E . Sexual function in patients with LUTS suggestive of BPH. Eur Urol 2001; 40 (Suppl 1): 19–22.

    Article  Google Scholar 

  10. Vallancien G, Emberton M, Harving N, van Moorselaar RJ . Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257–2261.

    Article  Google Scholar 

  11. Enzlin P, Mak R, Kittel F, Demyttenaere K . Sexual functioning in a population-based study of men aged 40-69 years: the good news. Int J Impot Res 2004; 16: 512–520.

    Article  CAS  Google Scholar 

  12. McCabe MP . Intimacy and quality of life among sexually dysfunctional men and women. J Sex Marital Ther 1997; 23: 276–290.

    Article  CAS  Google Scholar 

  13. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.

    Article  CAS  Google Scholar 

  14. Rosen RC, Seidman SN, Menza MA et al. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004; 16: 334–340.

    Article  CAS  Google Scholar 

  15. Dahn JR, Penedo FJ, Gonzalez JS et al. Sexual functioning and quality of life after prostate cancer treatment: considering sexual desire. Urology 2004; 63: 273–277.

    Article  Google Scholar 

  16. Bruskewitz R . Management of symptomatic BPH in the US: who is treated and how? Eur Urol 1999; 36 (Suppl 3): 7–13.

    Article  Google Scholar 

  17. Lukacs B . Management of symptomatic BPH in France: who is treated and how? Eur Urol 1999; 36 (Suppl 3): 14–20.

    Article  Google Scholar 

  18. AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. AUA Practice Guidelines Committee. J Urol 2003; 170: 530–547.

  19. Carbone Jr DJ, Hodges S . Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003; 15: 299–306.

    Article  Google Scholar 

  20. FLOMAX (tamsulosin hydrochloride) [prescribing information] Boehringer Ingelheim Pharmaceuticals, Inc.: Ridgefield, CT, 2005.

  21. Nickel JC, Fradet Y, Boake RC et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996; 155: 1251–1259.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G . Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–441.

    Article  Google Scholar 

  23. Baldwin K, Ginsberg P, Harkaway RC . Under-reporting of erectile dysfunction among men with unrelated urologic conditions. Int J Impot Res 2003; 15: 87–89.

    Article  CAS  Google Scholar 

  24. Kitai E, Vinker S, Kijner F, Lustman A . Erectile dysfunction – the effect of sending a questionnaire to patients on consultations with their family doctor. Fam Pract 2002; 19: 247–250.

    Article  Google Scholar 

  25. Hakim J, Subit M, Kandzari S, Zaslau S . Quality control in the screening of erectile dysfunction results of a survey. Urology 2002; 60: 125–129.

    Article  CAS  Google Scholar 

  26. Rutchik SD, Baudiere M, Wade M, Sullivan G, Rayford W, Goodman J . Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians. Urology 2001; 57: 146–150.

    Article  CAS  Google Scholar 

  27. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE . Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002; 324: 1059–1061.

    Article  Google Scholar 

  28. Fisher W, Rosen R, Eardley I et al. The multinational Men's Attitides to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns among men with erectile dysfunction. J Sex Med 2004; 1: 150–160.

    Article  Google Scholar 

  29. Wei J, Nuckolls J, Miner M, Rosen R, Roehrborn C . Differences in medical management of LUTS/BPH between PCPs and urologists [abstract]. J Urol 2006; 175: 3.

    Article  Google Scholar 

  30. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119–126.

    Article  Google Scholar 

  31. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: 533–539.

    Article  CAS  Google Scholar 

  32. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–2398.

    Article  CAS  Google Scholar 

  33. Resnick M, Seftel A, Rosen R, Roehrborn C . Alfuzosin 10 mg improves sexual function in BPH patients: preliminary results of a placebo controlled trial. Societe Internationale d'Urologie (SIU). Honolulu, Hawaii, 2004.

    Google Scholar 

  34. van Moorselaar RJ, Hartung R, Emberton M et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603–608.

    Article  Google Scholar 

  35. Elhilali M, Emberton M, Matzkin H et al. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in ‘real-life’ practice. BJU Int 2006; 97: 513–519.

    Article  CAS  Google Scholar 

  36. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K . A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192–200.

    Article  CAS  Google Scholar 

  37. De Rose AF, Carmignani G, Corbu C et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002; 68: 95–98.

    Article  CAS  Google Scholar 

  38. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC . Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836–839.

    Article  CAS  Google Scholar 

  39. Seftel AD, Sun P, Swindle R . The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341–2345.

    Article  Google Scholar 

Download references

Acknowledgements

This survey was sponsored by The American Foundation for Urologic Disease (AFUD) and funded through an unrestricted educational grant from sanofi-aventis. Patricia B Leinen, PhD, (Tri-Med Communications, Media, PA, USA) contributed to the preparation of the manuscript.

Author information

Authors and Affiliations

  1. Department of Urology, Case Western Reserve University, University Hospital of Cleveland, Cleveland, OH, USA

    A Seftel, R Rosen & L Kuritzky

Authors
  1. A Seftel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Kuritzky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Seftel.

Appendix A

Appendix A

Table a1 The questions included in the physician survey were:
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seftel, A., Rosen, R. & Kuritzky, L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 19, 386–392 (2007). https://doi.org/10.1038/sj.ijir.3901540

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901540

Keywords

This article is cited by

Search

Advanced search

Quick links